Evidence map›Paper›PMID 38627317›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2024

Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations.

Yanhua Wang, Jingwen Wei, Manyi Xu, Jing Xiang, Keda Shao, Yue Hao, Zhengbo Song

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yanhua Wang *The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, 310000, China.
Jingwen Wei *Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
Manyi Xu *The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, 310000, China.
Jing XiangThe Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, 310000, China.
Keda ShaoZhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
Yue HaoThe Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, 310000, China. deartreasurealicia@163.com.ORCID http://orcid.org/0000-0002-4725-6084
Zhengbo SongZhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China. songzb@zjcc.org.cn.ORCID http://orcid.org/0000-0002-2226-0570
Zhejiang Chinese Medical University · CNChinese Academy of Sciences · CNZhejiang Cancer Hospital · CN

Funding

Medical Scientific Research Foundation of Zhejiang Province No.2022KY653
6 · The paper itself

Abstract

backgroundMesenchymal epithelial transition factor (MET) is a rare oncologic driver gene, and information on immunotherapy for non-small cell lung cancer (NSCLC) patients with this driver gene is limited. Here we evaluate the efficacy and safety of immune checkpoint inhibitors (ICI) under different therapeutic regimen for NSCLC patients with MET alterations.

methodsFrom June 2019 to December 2023, we assessed the efficacy and toxicity of ICIs in 42 NSCLC patients with MET alterations. Survival curves were plotted using the Kaplan-Meier method and the Cox proportional hazards model applied for univariate and multivariate analyses. We assessed the size of target lesion according to RECIST v1.1, and objective response rate (ORR) was defined as the sum of complete response (CR) and partial response (PR), disease control rate (DCR) as the sum of CR, PR, and disease stable.

resultsA total of 42 NSCLC patients with MET alterations were included in this retrospective study, 10 was MET 14 skipping mutation and 32 was MET amplification. The ORR for ICI treatment was 30.95% and the DCR was 71.43%. Median progression-free survival (mPFS) and median overall survival (OS) were 4.40 and 13.97 months, respectively. There exists statistical differences between the mPFS of ICI monotherapy and combine ICI therapy (2.8 vs 7.8 months, p = 0.022). The incidence of drug-related adverse reactions was 47.62%, mainly bone marrow suppression (14.28%), immune-related pneumonia (7.14%), and liver function impairment (7.14%), and six patients (14.28%) experiencing grade 3 or above adverse events.

conclusionNSCLC patients with MET alterations can benefit from immunotherapy, especially the patients treated by combined ICI therapy. However, special attention should be paid to the occurrence of grade 3/4 adverse reactions while using the combined ICI therapy.

Indexed as

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsMutationProto-Oncogene Proteins c-metAdultAgedAged, 80 and overFemaleHumansImmunotherapyKaplan-Meier EstimateMaleMiddle AgedProgression-Free SurvivalProportional Hazards ModelsImmune Checkpoint InhibitorsMET protein, humanProto-Oncogene Proteins c-metImmunotherapyLung cancerMET alterationsMET amplificationNSCLC

Identifiers

PMID38627317
OpenAlexW4394843317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.